Skip to content
Screener

EPS (Diluted) at other companies

Amgen logo
AmgenAMGN
$4.37+64.9%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$12.23-4.5%
Gilead Sciences logo
Gilead SciencesGILD
-$8.45-642%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$1.15-5.5%
Biohaven logo
BiohavenBHVN
-$0.88+59.4%
Assembly Biosciences logo
Assembly BiosciencesASMB
-$0.54+53.8%

Other financials

Income statement

See full
Revenue$238.9M+19,583%
Gross profit$238.9M+19,763%
Operating income$73.5M+162%
Net income$80.1M+172%

Balance sheet

See full
Cash & equivalents$287.6M-6.1%
Total debt$93.3M-8.8%
Total equity$982.5M+3.7%
Total assets$1.2B+1.9%

Cash flow

See full
Operating cash flow-$132.4M-69.5%
CapEx$32.0K-98.7%
Free cash flow-$132.8M-66.5%

Valuation

See full
Market cap$1.48B+111%
Enterprise value$1.29B+159%
P/S4.9×-32.1×

Profitability

See full
Gross margin96.1%-2.7pp
Operating margin-92.4%-45.5pp
Net margin-83%-40.9pp
FCF margin-686.5%-273pp

Returns & leverage

See full
Return on equity-26.1%-7.9pp
Debt / equity0.1×0.0×
Current ratio-1.0×

Where this comes from

Reported directly by Vir Biotechnology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:20 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053549
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Total other income6,7927,62913,55726,227
Income (loss) before provision for income taxes80,259(110,788)(45,266)(231,737)
Provision for income taxes(179)(170)(349)(186)
Net income (loss)$80,080$(110,958)$(45,615)$(231,923)
Net income (loss) per share, basic$0.48$(0.80)$(0.29)$(1.68)
Net income (loss) per share, diluted$0.47$(0.80)$(0.29)$(1.68)
Weighted-average shares outstanding, basic167,719,015138,447,469157,613,578137,960,888
Weighted-average shares outstanding, diluted168,879,127138,447,469157,613,578137,960,888

Item 1. Financial Statements (unaudited)

FAQ

What is Vir Biotechnology, Inc.'s EPS (diluted)?
Vir Biotechnology, Inc. (VIR) reported EPS (diluted) of $0.47 in Q2 2026.
How has Vir Biotechnology, Inc.'s EPS (diluted) changed year-over-year?
Vir Biotechnology, Inc.'s EPS (diluted) increased by 158.8% year-over-year, from -$0.80 to $0.47.
What is the long-term trend for Vir Biotechnology, Inc.'s EPS (diluted)?
Over 3 years (2021 to 2025), Vir Biotechnology, Inc.'s EPS (diluted) has grown at a -6.9% compound annual growth rate (CAGR), from $3.90 to -$3.15.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Vir Biotechnology, Inc.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude